Back to Search
Start Over
Serum sST2 levels predict severe exacerbation of asthma.
- Source :
-
Respiratory Research . 9/3/2018, Vol. 19 Issue 1, pN.PAG-N.PAG. 1p. 4 Charts, 2 Graphs. - Publication Year :
- 2018
-
Abstract
- <bold>Background: </bold>Neutrophilic inflammation is associated with poorly controlled asthma. Serum levels of sST2, a soluble IL-33 receptor, increase in neutrophilic lung diseases. We hypothesized that high serum sST2 levels in stable asthmatics are a predictor for exacerbation within a short duration.<bold>Methods: </bold>This prospective observational study evaluated the serum sST2 levels of 104 asthmatic patients who were treated by a lung disease specialist with follow-ups for 3 months.<bold>Results: </bold>High serum sST2 levels (> 18 ng/ml) predicted severe asthma exacerbation within 3 months. Serum sST2 levels correlated positively with asthma severity (treatment step), airway H2O2 levels, and serum IL-8 levels. High serum sST2 levels and blood neutrophilia (> 6000 /μl) were independent predictors of exacerbation. We defined a post-hoc exacerbation-risk score combining high serum sST2 level and blood neutrophilia, which stratified patients into four groups. The score predicted exacerbation-risk with an area under curve of 0.91 in the receiver operating characteristic curve analysis. Patients with the highest scores had the most severe phenotype, with 85.7% showing exacerbation, airflow limitation, and corticosteroid-insensitivity.<bold>Conclusions: </bold>High serum sST2 levels predicted exacerbation within the general asthmatic population and, when combined with blood neutrophil levels, provided an exacerbation-risk score that was an accurate predictor of exacerbation occurring within 3 months. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 14659921
- Volume :
- 19
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Respiratory Research
- Publication Type :
- Academic Journal
- Accession number :
- 131555571
- Full Text :
- https://doi.org/10.1186/s12931-018-0872-2